Literature DB >> 12175668

D-dimer and platelet aggregability are related to thrombotic events in patients with peripheral arterial occlusive disease.

A Komarov1, E Panchenko, A Dobrovolsky, Yu Karpov, A Deev, E Titaeva, K Davletov, A Eshkeeva, L Markova.   

Abstract

AIMS: To evaluate the frequency of arterial thrombotic events in patients with peripheral arterial occlusive disease during 3-5 years of follow-up and to determine whether baseline levels of haemostatic factors were related to the risk of future thrombotic events. METHODS AND
RESULTS: One hundred and twenty-three patients, mean age 56 years, with peripheral arterial occlusive disease and intermittent claudication were followed prospectively for an average of 4.2 years. Fibrinogen, prothrombin fragment 1+2, D-dimer, tissue plasminogen activator, plasminogen activator inhibitor type I antigen and activity, plasmin-alpha(2)-antiplasmin complex, beta thromboglobulin and ADP-induced platelet aggregation were measured at the recruitment. Thirty-eight new vascular events (15 fatal) were identified. Age- (and other clinical and laboratory variables) -adjusted relative risks (RR) of thrombotic events were significantly elevated (P<0.05) per higher value of D-dimer (RR: 14.1, 95% CI 1.7;115.8) and platelet aggregation was low (RR: 4.6, 95% CI 1.3;16.3). Diabetes mellitus, cerebrovascular disease, and continuing deterioration of intermittent claudication at the recruitment were also independently associated with risk of thrombotic events in the multiple regression model (RR: 5.2, 95% CI 1.5;17.5; RR: 8.6, 95% CI 2.7;27.4; RR: 2.6, 95% CI 1.2;5.7 respectively).
CONCLUSION: Elevated level of D-dimer and low platelet aggregation are independent haemostatic predictors of thrombotic events in patients with peripheral arterial occlusive disease. Copyright 2002 The European Society of Cardiology Published by Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12175668     DOI: 10.1053/euhj.2001.3116

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  8 in total

Review 1.  Antithrombotic treatment for peripheral arterial disease.

Authors:  Daniel G Hackam; John W Eikelboom
Journal:  Heart       Date:  2006-10-11       Impact factor: 5.994

2.  Clot strength is negatively associated with ambulatory function in patients with peripheral artery disease and intermittent claudication.

Authors:  Karin Mauer; Andrew W Gardner; Tarun W Dasari; Julie A Stoner; Steve M Blevins; Polly S Montgomery; Jorge F Saucedo; J Emilio Exaire
Journal:  Angiology       Date:  2014-04-27       Impact factor: 3.619

Review 3.  Criticial limb ischemia: epidemiology.

Authors:  Mark G Davies
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Oct-Dec

4.  Gender-Related Difference in D-Dimer Level Predicts In-Hospital Heart Failure after Primary PCI for ST-Segment Elevation Myocardial Infarction.

Authors:  Li Li; Wei Wang; Tai Li; Ying Sun; Yanjun Gao; Lin Wang; Heng-Chen Yao
Journal:  Dis Markers       Date:  2021-08-10       Impact factor: 3.434

5.  The Clinical Utility of D-Dimer and Prothrombin Fragment (F1+2) for Peripheral Artery Disease: A Prospective Study.

Authors:  Sara Arfan; Abdelrahman Zamzam; Muzammil H Syed; Shubha Jain; Niousha Jahanpour; Rawand Abdin; Mohammad Qadura
Journal:  Biomedicines       Date:  2022-04-11

6.  Epidemiology of Peripheral Artery Disease and Polyvascular Disease.

Authors:  Aaron W Aday; Kunihiro Matsushita
Journal:  Circ Res       Date:  2021-06-10       Impact factor: 23.213

7.  Blood coagulation and the risk of atherothrombosis: a complex relationship.

Authors:  Henri Mh Spronk; Danielle van der Voort; Hugo Ten Cate
Journal:  Thromb J       Date:  2004-12-01

8.  Assessment of Risk Factors for Drug Resistance of Dual Anti Platelet Therapy After PCI.

Authors:  Lijie Zhang; Ying Lv; Jianyu Dong; Nana Wang; Zhan Zhan; Yuan Zhao; Shanshan Jiang
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.